Research Site

Linfen 041099

1 studies enrolling now · 1 studies all time

What they study most

Gastroesophageal Junction Adenocarcinoma, HER2-positive Gastric Cancer

Studies at this site

• A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer — Recruiting now